AvenCell derives its name from the French word 'avenir' to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/22/24 | $112,000,000 | Series B |
Blackstone Life Sciences Eight Roads F-Prime Capital Partners Novo Holdings  NYBC Ventures Piper Heartland Healthcare Capital | undisclosed |
